

## Synthesis of Benzoazepine Derivatives via Azide Rearrangement and Evaluation of Their Antianxiety Activities

Onrapak Reamtong, Sarawut Lapmanee, Jumreang Tummatorn,\* Nitwaree Palavong, Charnsak Thongsornkleeb, and Somsak Ruchirawat

Cite This: <https://doi.org/10.1021/acsmchemlett.1c00275>

Read Online

ACCESS |



Metrics &amp; More




Article Recommendations



Supporting Information

**ABSTRACT:** A new synthetic method for the construction of benzoazepine analogues has been developed employing *ortho*-arylmethylbenzyl azide derivatives as precursors using an azide rearrangement reaction. In this work, 14 benzoazepine compounds were successfully synthesized in moderate to excellent yields. All synthetic benzoazepines were evaluated for their cytotoxicity against normal human kidney cell line (HEK cell). The results showed that compound **18c** had the lowest cytotoxicity ( $IC_{50} = 65.68 \mu M$ ) among tested compounds, which was comparable with the antianxiety drug diazepam ( $IC_{50} = 87.90 \mu M$ ). Based on the cytotoxicity results, five benzoazepine analogues (compounds **18c**, **18h**, **18j**, **18n**, and **18p**) were selected to determine the antianxiety effect on stressed rats using elevated plus maze (EPM) and open field test (OFT) methods. Interestingly, compound **18c** showed better anxiolytic activity than diazepam without a sedative effect by showing superior hyperlocomotor activity. Therefore, this discovery could pave the way for drug development to treat patients with anxiety disorder.

**KEYWORDS:** Benzoazepine, Azide, Antianxiety, Diazepam



The impact of rapid growth of technology and social media has changed human behavior in both positive and negative manners.<sup>1,2</sup> The negative effects can lead to mental health problems such as major depressive disorder and dysthymic disorder.<sup>3</sup> In addition, genetics is another factor of this symptom. Anxiety disorder is a type of psychiatric disorder involving an excessive behavioral response to stress.<sup>4</sup> This symptom can affect job duties, career path, relationship among friends, and family. Nowadays, the prevalence of this disorder has increased every year and could contribute to depression and suicide.<sup>5</sup> Due to these negative effects, patients need behavioral therapy and/or medical treatment. However, patients have different responsiveness to the drug treatment. Therefore, a variety of drugs is needed for the treatment of these symptoms.<sup>6</sup> The benzoazepine core structure is a well-known pharmacophore that is present in several mood disorder drugs,<sup>7,8</sup> especially in the class of mood-stabilizing drugs such as imipramine, diazepam, and lorazepam.<sup>9,10</sup> In addition, this core structure shows various biological activities associated with several commercial drugs. For example, this core structure is present in commercial anticancer drugs such as olanzapine, rucaparib, clozapine, anthramycin, and tomaymycin.<sup>11–14</sup> Furthermore, the benzoazepine motif plays key roles in other biological activities including antibacterial,<sup>15</sup> anticonvul-

sant,<sup>16,17</sup> anti-HIV-1,<sup>18,19</sup> and antihypertension properties<sup>20</sup> (Figure 1).

As a result of its prominent biological activities, the benzoazepine core structure has a high potential to be used in drug design to develop novel pharmaceutical agents. According to our research interest in azide chemistry,<sup>21–27</sup> we envision that benzoazepine could be prepared using azide as the nitrogen source. In addition, azide was employed in a broad range of reactions for the synthesis of *N*-containing compounds, including *N*-methylarylamines, indoloquinolines, quinolines, tetrahydroquinolines, and phenanthridines.<sup>21–27</sup> Our research group has been interested in azide rearrangement chemistry to develop new methods for the synthesis of biologically active compounds. Benzyl azide derivatives were employed as a common precursor for the generation of an iminium ion intermediate, which could react with a variety of nucleophiles either in an intramolecular or intermolecular reaction to provide the corresponding *N*-containing com-

Received: May 13, 2021

Accepted: July 13, 2021




Figure 1. Representatives of commercial benzoazepine drugs.


pounds as shown in Scheme 1. In this work, we aimed to utilize our research background in azide rearrangement chemistry in the design and synthesis of benzoazepine derivatives for the development of an anti-anxiety agent (Scheme 1).

In this study, *ortho*-aryl-methylbenzyl azide derivatives (17) were prepared as substrates for the synthesis of benzoazepines. The results are reported in Scheme 2. 2-Formylphenyl boronic acid 19a was used as the starting material, which was coupled with 3-methoxybenzyl bromide 20c-Br (X = Br) via Suzuki cross-coupling<sup>28,29</sup> to obtain biarylmethane aldehyde product 21c in 36% yield along with the formation of a benzylethyl ether side product. Therefore, toluene was used instead of EtOH to avoid the formation of this side product and provide only compound 21c in 48% yield due to the low solubility of the boronic acid in toluene. Later on, we found that the best partner to couple with 2-formylboronic acid 19a via a Suzuki cross-coupling reaction was 3-methoxybenzyl chloride 20c-Cl (X = Cl), which could give the corresponding biarylmethane derivatives 21c in 76% yield. Therefore, commercially available benzyl chloride derivatives were employed as the partner for a Suzuki cross-coupling reaction. However, in some cases, benzyl bromide derivatives were used for the synthesis of compounds 21, because they were commercially available. The results are demonstrated in Scheme 2.


Then, substrate 21 was reduced using NaBH<sub>4</sub> in MeOH to provide the corresponding alcohol product. After purification, this alcohol was converted to a benzyl bromide derivative using

## Scheme 1. Our Proposed Synthetic Method


### Our previous work




### A. Intermolecular cyclization



### B. Intramolecular cyclization




### C. This work





































PBr<sub>3</sub> in DCM. Upon completion, DCM was removed to give crude product, which was then taken up in DMSO before NaN<sub>3</sub> was added. The reactions could provide the desired products 17 in moderate to good yields in three steps. However, *ortho*-aryl-methylbenzyl aldehydes 21d and 21m could not be purified, and they were therefore subjected to the reduction conditions to provide alcohol products 28d and 28m in good yields. Furthermore, alcohol products from the reduction of compounds 21g, 21j–21l, 21p, and 21s could not be purified. Therefore, they were directly used in the bromination and azidation steps to give the corresponding azides 17 in moderate to good yields. In the case of substrate 17f, it was prepared using the same protocol as shown in Scheme 2. However, both aldehyde and alcohol products could not be obtained in pure forms; thus, the bromination and azidation reactions were carried out in successive order to give azide 17f in 27% overall yield (Scheme 3). In addition, a different method was used for the preparation of compound 17e. Compound 22e, prepared from a Friedel–Crafts reaction between phthalic anhydride and 1,2,4-trimethoxybenzene followed by esterification, was employed as the starting material. Compound 22e was subjected to reduction conditions to give compound 23e, which was converted to the corresponding product 17e by reduction, bromination, and azidation as shown in Scheme 3.

Substrate 17t, which would cyclize to give an eight-membered ring product, was prepared by the coupling reaction between 2-bromobenzaldehyde (24) and 3-methoxystyrene (25) via a Heck reaction to give product 26 in 84% yield. Then, this compound was hydrogenated using Pd/C and hydrogen gas to obtain compound 27 in 95% yield. Finally, the aldehyde moiety was converted to azide using the same



Table 2. Substrate Scope<sup>a</sup>
















Entry	Substrate	Product	Yield	Entry	Substrate	Product	Yield
1	 17a	-	0%	11	 17k	 27k	28%
2	 17b	-	0%	12	 17l	 27l	45%
3	 17c	 18c	93%	13	 17m	 18m	95%
4	 17d	 18d	93%	14	 17n	 18n	99%
5	 17e	 27e	40%	15	 17o	 18o	94%
6	 17f	 27f	15%	16	 17p	 18p	75%
7	 17g	 18g	73%	17	 17q	 18q	92%
8	 17h	 18h	98%	18	 17r	 18r	75%
9	 17i	 18i	54%	19	 17s	 18s	12%
10	 17j	 18j	97%	20	 17t	 18t	53%

<sup>a</sup>Isolated yield.

crucial in this conversion. Next, the reaction of a substrate containing 3-phenoxybenzyl yielded the desired product **18g** in a slightly lower yield (73%), possibly due to the lower nucleophilicity of the 3-phenoxybenzyl group. To evaluate the

electronic effect of R<sup>1</sup>, several substrates were prepared and subjected to the optimal conditions. Substrate **17h** containing a fluorine atom at position 7 on aryl ring A was converted to the desired product **18h** in 98% yield, while substrate **17i**

Table 3. In Vitro Cytotoxic Activity of Benzoazepine Analogues **18**<sup>a</sup> against Normal Human Kidney Cell Line (HEK)

Entry	Compound	HEK (IC <sub>50</sub> μM)	Entry	Compound	HEK (IC <sub>50</sub> μM)
1		65.68	8		0.16
2		6.44	9		0.77
3		4.43	10		12.64
4		13.73	11		2.29
5		2.12	12		1.09
6		14.16	13		14.46
7		6.19	14		14.11
15	Diazepam (IC <sub>50</sub> μM)	87.90			


<sup>a</sup>Benzoazepine analogues were tested as free bases.

containing a methoxy group at position 8 on aryl ring A underwent the reaction to provide the benzoazepine product **18i** in a much lower yield (54%). This was to be expected as electron-rich benzyl azide derivatives provided unstable iminium ion intermediates leading to decomposition and giving products in low yields. On the contrary, the substrate containing a chlorine atom at the same position could furnish the desired product **18j** in excellent yield (97%).

Next, substrates bearing a more highly nucleophilic group than the benzyl group, such as  $\alpha$ - and  $\beta$ -naphthylmethyl groups (**17k** and **17l**), were examined. However, the reactions were unsuccessful in both cases. Substrates containing a variety of R<sup>1</sup> on a 1-(azidomethyl)-2-(3-methoxybenzyl)benzene core structure were next studied (entries 13–19). Compound **17m** (R<sup>1</sup> = 7-F) smoothly converted to the desired product in 95% yield. Moreover, compounds containing a fluorine atom at other positions, compounds **17n** (R<sup>1</sup> = 9-F) and **17o** (R<sup>1</sup> = 10-F), were also examined. The reactions of these substrates provided the corresponding products in 99 and 94% yields, respectively. Furthermore, substrates with chlorine substituents were prepared and subjected to the optimal conditions. Thus, the reactions of compounds **17p** (R<sup>1</sup> = 8-Cl) and **17q** (R<sup>1</sup> = 9-Cl) gave the corresponding products **18p** and **18q** in 75 and 92% yields, respectively. These results showed that substrates containing a halogen atom at various positions were well-tolerated under these conditions; their presence did not

significantly affect the yields of products. In the case of substrate **17r**, bearing 5-methoxybenzyl azide, the reaction provided the desired product in 75% yield, which was better than the result of compound **17i** possibly due to the OMe group being more electron-donating than the OPh group, making the aryl ring become more nucleophilic in addition to an iminium ion intermediate. However, these conditions were not compatible with the dioxymethylene protecting group in substrate **17s**, leading to decomposition of the substrate to give the corresponding product **18s** in 12% yield. Moreover, this method was also applied to synthesize eight-membered product **18t** (entry 20), which produced a 53% yield of the eight-membered product.

In vitro cytotoxicity evaluation: Upon obtaining these synthetic benzoazepine derivatives, all of them were subjected to evaluation of their cytotoxicity. The results are shown in Table 3. A total of 14 benzoazepine analogues in their free base forms were subjected to in vitro cytotoxicity evaluation. The cytotoxic assay was performed against a normal human kidney cell line (HEK) using the MTT method.<sup>31</sup> The cytotoxicity of diazepam was employed to compare with our tested compounds. It is important to note that several tested compounds have low toxicity, especially compound **18c**, which had the lowest toxicity (IC<sub>50</sub> = 65.68 μM) among the series and had slightly higher cytotoxicity than diazepam (IC<sub>50</sub> = 87.90 μM), which is currently used as an antianxiety drug.




**Figure 2.** Effect of benzoazepine analogues on anxiety- and locomotion-related behaviors in rats as determined by EPM (three rats per group). (A) The anxiety index reflected the exploratory behaviors (the greater anxiety index indicated higher anxiety). (B) The total open arm entry in normal rats with acute 0.4, 2, or 10 mg/kg diazepam (DZP) or benzoazepine analogues (**18c**, **18h**, **18j**, **18n**, and **18p**). \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$  compared with the control nonstress vehicle (control)-treated group. † $p < 0.05$ , †† $p < 0.01$ , and ††† $p < 0.001$  compared with the stress DZP-treated group.

However, the toxicity increased when dimethoxy groups were placed in aryl ring B of compound **18d** having an  $IC_{50}$  value of  $6.44 \mu\text{M}$ . Then, a substrate containing an OPh group at position 3 was examined (entry 3, compound **18g**) with the toxicity enhanced to give an  $IC_{50}$  value of  $4.43 \mu\text{M}$ . The results from entries 1–3 suggested that compounds with an anisole moiety exhibited less toxicity than dimethylresorcinol and diaryl ether moieties. Interestingly, the addition of a fluorine substituent at position 7 of aryl ring A in compound **18h** could decrease the toxicity of the compound with an  $IC_{50}$  value of  $13.73 \mu\text{M}$  when compared with compound **18g**. However, the toxicity of compound **18i** was increased when a methoxy substituent was installed at carbon position 8 on aryl ring A, giving an  $IC_{50}$  value of  $2.12 \mu\text{M}$ . Therefore, we decided to prepare the benzoazepine derivatives containing an anisole moiety on aryl ring B while also varying the substituent groups on aromatic ring A. Unexpected results were obtained when the substrate contained a fluorine atom at position 7: compound **18m** ( $IC_{50} = 6.19 \mu\text{M}$ ) exhibited significantly higher toxicity than compound **18h** with an  $IC_{50}$  value of  $13.73 \mu\text{M}$ . In addition, we found that when a fluorine atom was located at positions 9 (compound **18n**) and 10 (compound **18o**), it provided even higher toxicity with  $IC_{50}$  values of  $0.16$  and  $0.77 \mu\text{M}$ , respectively. Changing from a fluorine substituent to a chlorine atom, compound **18p**, containing a chlorine atom at position 8, showed lower toxicity with an  $IC_{50}$  value of  $12.64 \mu\text{M}$ , while compound **18q**, bearing a chlorine atom at position 9, showed higher toxicity with an  $IC_{50}$  value of  $2.29 \mu\text{M}$ .

In the case of compound **18r** containing a methoxy group at position 8, it also provided an unimpressive result with an  $IC_{50}$

value of  $1.09 \mu\text{M}$ , whereas compound **18s** containing a methylenedioxy moiety could decrease the toxicity of the benzoazepine analogue with an  $IC_{50}$  value of  $14.46 \mu\text{M}$ . However, the synthesis of this compound gave the desired product in low yield. In further evaluation, the substrate with a larger cyclic amine, tetrahydrodibenzoazocine **18t**, was prepared, which also provided the product in a moderate yield. This compound showed an  $IC_{50}$  value of  $14.11 \mu\text{M}$ . For the biological activity evaluation, the four lowest toxicity benzoazepine derivatives were selected. However, compounds **18s** and **18t** were excluded from the list, because the synthesis of these compounds provided only low to moderate yields of products that were not suitable for further study in drug development. Therefore, compounds **18c**, **18h**, **18j**, and **18p** were selected to test for their antianxiety property. In addition, we also selected compound **18n** having the highest toxicity in this study to compare the results with the lowest toxicity compounds.

Effect of benzoazepine analogues on anxiety- and locomotion-related behaviors in rats: In this study, benzoazepines **18c**, **18h**, **18j**, **18n**, and **18p** were examined for their anxiolytic property in rats. The stress was induced by restraint stress induction. This method was accomplished to induce the anxiety-like behaviors in rats in numerous studies. Initially, stress was induced in rats by being immobilized in a plastic restrainer for 2 h/day for 14 days. The stress was evaluated using two methods including elevated plus maze (EPM) and open field test (OFT).<sup>32,33</sup> As compared to the control group, the 2-week stress induction showed anxiety-like behavior as demonstrated by both EPM and OFT. To establish a suitable dose of substances for antianxiety evaluation in rats, diazepam




**Figure 3.** Effect of benzoazepine analogues on anxiety-like behaviors in stressed rats as determined by EPM (six rats per group). (A) The percent open arm entry, (B) the percent open arm time, and (C) the anxiety index in stressed rats with acute 2 mg/kg diazepam (DZP) or benzoazepine analogues (18c, 18h, 18j, 18n, and 18p). \*\* $p < 0.01$  and \*\*\* $p < 0.001$  compared with the control nonstress vehicle (Con)-treated group. † $p < 0.05$  and ††† $p < 0.001$  compared with the stress vehicle (Veh)-treated group.

(DZP) and benzoazepine analogues (18c, 18h, 18j, 18n, and 18p) were employed for the screening for the optimal dosage using EPM. The results were illustrated in Figure 2. For the EPM test, 2 mg/kg DZP-treated rats showed a significant decrease in anxiety index (Figure 2A), while 0.4 and 10 mg/kg DZP-treated rats did not change in the total open arm entry. Similarly, the treatment of 2 mg/kg of benzoazepine analogues (18c, 18h, 18j, 18n, and 18p) had not affected locomotor activity as compared to the vehicle control group (Figure 2B). Therefore, diazepam (2 mg/kg) and benzoazepine analogues (2 mg/kg) were proposed to be a suitable anxiolytic dose for the study of anxiolytic-like effects of benzoazepine analogues in the animal model.

The elevated plus maze (EPM) test: The effect of benzoazepine analogues (18c, 18h, 18j, 18n, and 18p) on anxiety-like behaviors in nonstressed control rats and stressed rats was determined using EPM. This protocol correlated the fear of novelty and open spaces with stress. The behavior of rats with a high percentage of the frequency of open-space entries and high percentage of time spent in the open arms was used to indicate a decrease of stress level in rats. To determine the therapeutic effects of benzoazepine analogues on the anxiety-like behaviors, stressed rats were administered with 2 mg/kg of test compounds for 30 min prior to the behavioral tests. In this study, all experiments were conducted employing six rats per group. The results in Figure 3A showed that the

percentage of the open arm entry of nonstressed rats (Con) was significantly higher than the stressed rats (Veh). These results showed that the restraint stress induction was successful to induce anxiety-like behaviors in rats (Veh). Next, the stressed rats were treated with diazepam (DZP), an antianxiety drug, which resulted in a slightly lower percent open arm entry compared with Con. These results showed the effectiveness of diazepam, which corresponded with the results from other reported works. Acute amphetamine withdrawal rats were found to show increased anxiety-like behavior in the EPM.<sup>34</sup> Diazepam administration demonstrated anxiolytic efficacy in hemiparkinsonian rats.<sup>35</sup> In this study, five synthetic benzoazepine analogues (18c, 18h, 18j, 18n, and 18p) were evaluated for an antianxiety property. Interestingly, compound 18c containing a methoxy group at position 3 of aromatic ring B provided a higher percent open arm entry than the DZP standard. In addition, this compound showed very low cytotoxicity against normal human kidney cell line (HEK cells) with a comparable  $IC_{50}$  to diazepam. Then, compound 18h containing a fluorine atom at position 7 of aromatic ring A and a phenoxy group at position 3 of aromatic ring B was employed and showed the best activity among the tested compounds and the DZP standard. Compound 18j containing a phenoxy group at the same position with 18h and chlorine atom at position 8 of aromatic ring A showed slightly lower activity than compound 18h but provided a comparable



**Figure 4.** Effect of benzoazepine analogue treatments on anxiety-like behaviors and locomotor activity in stressed rats as determined by OFT (six rats per group). (A) The inner zone time, (B) the outer zone time, (C) the number of total lines crossed in stressed rats with acute 2 mg/kg diazepam (DZP) or benzoazepine analogues (18c, 18h, 18j, 18n, and 18p). \* $p < 0.05$  and \*\*\* $p < 0.001$  compared with the control nonstress vehicle (Veh)-treated group. †† $p < 0.01$  and ††† $p < 0.001$  compared with the stress vehicle (Veh)-treated group. # $p < 0.05$ , ## $p < 0.01$ , and ### $p < 0.001$  compared with the stress DZP-treated group.

activity to DZP. In the case of compound 18n containing a fluorine atom and methoxy group at positions 9 of ring A and 3 of ring B, respectively, displayed the lowest percent open arm entry among tested compounds. Meanwhile, compound 18p containing a chlorine atom and methoxy group at positions 8 of ring A and 3 of ring B, respectively, provided a comparable activity with the diazepam standard. This study showed that all tested benzoazepines had a significant effect in reducing the anxiety level of stressed rats, especially compounds 18c and 18h, which showed higher efficacy than the diazepam drug. In addition, time spent in open arms was also examined as shown in Figure 3B. The results showed that only compound 18c showed the highest amount of time spent in the open arms by the stressed rats when compared with DZP and other synthetic benzoazepines (18h, 18j, 18n, and 18p). In addition, compounds 18h, 18j, and 18p showed a comparable amount of time spent in open arms with DZP, whereas compound 18n had the lowest ability to reduce anxiety in the stressed rats. Figure 3C indicated the increased anxiety level of rats. These results clearly showed an anxiolytic property of benzoazepine analogues in stressed rats. It is important to note that compound 18c gave the best antianxiety property compared with diazepam and other benzoazepine analogues.

The open field test (OFT) test: The effect of benzoazepine analogue treatments on anxiety-like behaviors and locomotor

activity in stressed rats was determined by an OFT test (six rats per group). According to the OFT results, restraint stress induction was successful to induce anxiety-like behaviors in rats as shown in Figure 4. For the OFT test, a decrease in the inner zone time indicated a high anxiety level of rats while changing the number of total lines crossed and rearing correlated to locomotor activity and a tendency to want to explore the spaces of rats, respectively. In our study, the results showed that the stressed rats had a lower amount of time spent in the inner zone (Figure 4A) and spent more time in the outer zone (Figure 4B) without any alteration in the number of total lines crossed (Figure 4C). Next, the stressed rats were treated with the DZP standard when measuring a stress response; we found that rats spent more time both in the inner and outer zones (Figure 4A,B) and also showed a lower number of rearing than vehicle-treated stressed rats (Veh) (Figure 4C). In addition, the treatment of stressed rats with DZP could alter the number of line crossings in the OFT test (Figure 4C). Compared to vehicle-treated stressed rats (Veh, Figure 4A), rats treated with benzoazepine analogues, 18c, 18h, 18j, 18n, and 18p, displayed a significant increase in the time spent in the inner zone of OFT (Figure 4A). It should be noted that compound 18n demonstrated a higher increase in the amount of time spent in the inner zone by the stressed rats compared to the DZP-treated ones. Moreover, all tested compounds,

including DZP, showed hyperlocomotor activity in stressed rats as illustrated in Figure 4C. Therefore, these results suggested that benzoazepine analogues possessed anxiolytic effects and could enhance the behavior response in stressed rats without the sedative effect.

In conclusion, we have developed a new method for the synthesis of benzoazepine analogues using azide rearrangement chemistry. In this work, 14 derivatives were successfully prepared in moderate to excellent yields. All benzoazepine analogues were evaluated for their cytotoxicity against normal human kidney cell line (HEK cell). The results showed that several compounds had low cytotoxicity. A total of five derivatives were employed to evaluate the antianxiety property including compounds 18c, 18h, 18j, 18n, and 18p. In this work, we discovered that compound 18c had higher potency to reduce the anxiety of the stressed rats and also had very low cytotoxicity comparable with diazepam. Therefore, compound 18c could be used as a lead compound for further drug development to treat patients with anxiety disorder.

## ■ ASSOCIATED CONTENT

### SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsmmedchemlett.1c00275>.

Copies of  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for compounds 21a–21c, 21g–21i, 21n–21s, 23e, and 26. Copies of  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for compounds 28a–28d, 28h, 28i, 28m–28o, 28q, and 28r. Copies of  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for compounds 17a–17t. Copies of  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for compounds 18a–18d, 18g–18j, 18m–18t, 27e, 27f, 27k, and 27l. Chromatographic purity analysis of compounds 18c, 18h, 18j, 18n, and 18p using HPLC (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

**Jumreang Tummatorn** – Program on Chemical Sciences, Chulabhorn Graduate Institute, Center of Excellence on Environmental Health and Toxicology, CHE, Ministry of Education, Bangkok 10210, Thailand; Chulabhorn Research Institute, Bangkok 10210, Thailand;  [orcid.org/0000-0002-1662-151X](https://orcid.org/0000-0002-1662-151X); Email: [jumreang@cri.or.th](mailto:jumreang@cri.or.th)

### Authors

**Onrapak Reamtong** – Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand  
**Sarawut Lapmanee** – Preclinical Department, Faculty of Medicine, Siam University, Bangkok 10160, Thailand  
**Nitwaree Palavong** – Program on Chemical Sciences, Chulabhorn Graduate Institute, Center of Excellence on Environmental Health and Toxicology, CHE, Ministry of Education, Bangkok 10210, Thailand  
**Charnsak Thongsornkleeb** – Program on Chemical Sciences, Chulabhorn Graduate Institute, Center of Excellence on Environmental Health and Toxicology, CHE, Ministry of Education, Bangkok 10210, Thailand;  [orcid.org/0000-0003-2653-5137](https://orcid.org/0000-0003-2653-5137)  
**Somsak Ruchirawat** – Program on Chemical Sciences, Chulabhorn Graduate Institute, Center of Excellence on Environmental Health and Toxicology, CHE, Ministry of

Education, Bangkok 10210, Thailand; Chulabhorn Research Institute, Bangkok 10210, Thailand

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acsmmedchemlett.1c00275>

## Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This research project is supported by Thailand Science Research and Innovation (FFB640035 Project code S0170) and Project code 69864, Chulabhorn Graduate Institute, Chulabhorn Royal Academy, Chulabhorn Research Institute, and the Center of Excellence on Environmental Health and Toxicology, Science & Technology Postgraduate Education and Research Development Office (PERDO), Ministry of Education. In addition, we would like to thank Ms. Warabhorn Rodphon for drawing the table of content graphic in this manuscript.

## ■ REFERENCES

- (1) Abbas, J.; Aman, J.; Nurunnabi, M.; Bano, S. The impact of social media on learning behavior for sustainable education: Evidence of students from selected universities in Pakistan. *Sustainability* **2019**, *11*, 1683.
- (2) Twenge, J. M. Why increases in adolescent depression may be linked to the technological environment. *Curr. Opin. Psychol.* **2020**, *32*, 89–94.
- (3) Otte, C.; Gold, S. M.; Penninx, B. W.; Pariante, C. M.; Etkin, A.; Fava, M.; Mohr, D. C.; Schatzberg, A. F. Major depressive disorder. *Nat. Rev. Dis. Primers* **2016**, *2*, 16065.
- (4) Smoller, J. W. The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. *Neuropsychopharmacology* **2016**, *41*, 297–319.
- (5) Hawton, K.; Casañas i Comabella, C.; Haw, C.; Saunders, K. Risk factors for suicide in individuals with depression: a systematic review. *J. Affective Disord.* **2013**, *147*, 17–28.
- (6) Dimidjian, S.; Hollon, S. D.; Dobson, K. S.; Schmalzing, K. B.; Kohlenberg, R. J.; Addis, M. E.; Gallop, R.; McGlinchey, J. B.; Markley, D. K.; Gollan, J. K.; et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J. Consult. Clin. Psychol.* **2006**, *74*, 658.
- (7) Cuijpers, P.; Sijbrandij, M.; Koole, S. L.; Andersson, G.; Beekman, A. T.; Reynolds, C. F., III The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. *World Psychiatry* **2013**, *12*, 137–148.
- (8) Andrés, J. I.; Alcázar, J.; Alonso, J. M.; Díaz, A.; Fernández, J.; Gil, P.; Iturrino, L.; Matesanz, E.; Meert, T. F.; Megens, A.; et al. Synthesis and structure–activity relationship of 2-(aminoalkyl)-2, 3, 3a, 8-tetrahydrodibenzo [c, f] isoxazolo [2, 3-a] azepine derivatives: a novel series of 5-HT<sub>2A/2C</sub> receptor antagonists. Part 1. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 243–248.
- (9) Rickels, K.; DeMartinis, N.; García-España, F.; Greenblatt, D. J.; Mandos, L. A.; Rynn, M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. *Am. J. Psychiatry* **2000**, *157*, 1973–1979.
- (10) Rickels, K.; Chung, H. R.; Csanalosi, I. B.; Hurowitz, A. M.; London, J.; Wiseman, K.; Kaplan, M.; Amsterdam, J. D. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. *Arch. Gen. Psychiatry* **1987**, *44*, 862–866.
- (11) Nielsen, J.; Correll, C. U.; Manu, P.; Kane, J. M. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? *J. Clin. Psychiatry* **2013**, *74*, 603–613.

- (12) Ahmed, K.; Turk, J. L. Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro. *Cancer Immunol. Immunother.* **1989**, *28*, 87–92.
- (13) White, A. W.; Almassy, R.; Calvert, A. H.; Curtin, N. J.; Griffin, R. J.; Hostomsky, Z.; Maegley, K.; Newell, D. R.; Srinivasan, S.; Golding, B. T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase. *J. Med. Chem.* **2000**, *43*, 4084–4097.
- (14) Musella, A.; Bardhi, E.; Marchetti, C.; Vertechy, L.; Santangelo, G.; Sassu, C.; Tomao, F.; Rech, F.; D'Amelio, R.; Monti, M.; et al. Rucaparib: an emerging parp inhibitor for treatment of recurrent ovarian cancer. *Cancer Treat. Rev.* **2018**, *66*, 7–14.
- (15) Johnson, P. D.; Aristoff, P. A.; Zurenko, G. E.; Schaadt, R. D.; Yagi, B. H.; Ford, C. W.; Hamel, J. C.; Stapert, D.; Moerman, J. K. Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 4197–4200.
- (16) Wang, R.; Jin, R.-X.; Qin, Z.-Y.; Bian, K.-J.; Wang, X.-S. Novel and facile synthesis of 1-benzazepines via copper-catalyzed oxidative C (sp<sup>3</sup>)-H/C (sp<sup>2</sup>)-H cross-coupling. *Chem. Commun.* **2017**, *53*, 12229–12232.
- (17) Shalini, M.; Yogeewari, P.; Sriram, D.; Stables, J. Cyclization of the semicarbazone template of aryl semicarbazones: synthesis and anticonvulsant activity of 4, 5-diphenyl-2H-1, 2, 4-triazol-3 (4H)-one. *Biomed. Pharmacother.* **2009**, *63*, 187–193.
- (18) Seto, M.; Miyamoto, N.; Aikawa, K.; Aramaki, Y.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Shiraiishi, M. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety. *Bioorg. Med. Chem.* **2005**, *13*, 363–386.
- (19) Chumpradit, S.; Kung, M. P.; Billings, J. J.; Kung, H. F. Synthesis and resolution of (±)-7-chloro-8-hydroxy-1-(3'-iodophenyl)-3-methyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor [Erratum to document cited in CA114 (13): 122017d]. *J. Med. Chem.* **1991**, *34*, 3405–3405.
- (20) Kartsev, V. G.; Zubenko, A. A.; Morkovnik, A. S.; Divaeva, L. N. A facile, one pot method for the synthesis of 4-acyl-1, 2-dihydro-3-benzazepines, based on the ring expansion of natural and synthetic 3, 4-dihydroisoquinoline pseudo bases. *Tetrahedron Lett.* **2015**, *56*, 6988–6993. (b) Kawase, M.; Saito, S.; Motohashi, N. Chemistry and biological activity of new 3-benzazepines. *Int. J. Antimicrob. Agents* **2000**, *14*, 193–201.
- (21) Tummatorn, J.; Krajangsri, S.; Nourseeda, K.; Thongsornkleeb, C.; Ruchirawat, S. A new synthetic approach to 6-unsubstituted phenanthridine and phenanthridine-like compounds under mild and metal-free conditions. *Org. Biomol. Chem.* **2014**, *12*, 5077–5081.
- (22) Aroonkit, P.; Thongsornkleeb, C.; Tummatorn, J.; Krajangsri, S.; Mungthin, M.; Ruchirawat, S. Synthesis of isocryptolepine analogues and their structure–activity relationship studies as antiplasmodial and antiproliferative agents. *Eur. J. Med. Chem.* **2015**, *94*, 56–62.
- (23) Tummatorn, J.; Thongsornkleeb, C.; Ruchirawat, S. Acid-promoted rearrangement of arylmethyl azides: applications toward the synthesis of N-arylmethyl arenes and polycyclic heteroaromatic compounds. *Tetrahedron* **2012**, *68*, 4732–4739.
- (24) Tummatorn, J.; Poonsilp, P.; Nimmual, P.; Janprasit, J.; Thongsornkleeb, C.; Ruchirawat, S. Regioselective synthesis of 3-bromoquinoline derivatives and diastereoselective synthesis of tetrahydroquinolines via acid-promoted rearrangement of arylmethyl azides. *J. Org. Chem.* **2015**, *80*, 4516–4525.
- (25) Akkachairin, B.; Tummatorn, J.; Khamswan, N.; Thongsornkleeb, C.; Ruchirawat, S. Domino N2-Extrusion–Cyclization of Alkynylarylketone Derivatives for the Synthesis of Indoloquinolines and Carbocycle-Fused Quinolines. *J. Org. Chem.* **2018**, *83*, 11254–11268.
- (26) Nimmual, P.; Tummatorn, J.; Thongsornkleeb, C.; Ruchirawat, S. Utility of nitrogen extrusion of azido complexes for the synthesis of nitriles, benzoxazoles, and benzisoxazoles. *J. Org. Chem.* **2015**, *80*, 8657–8667.
- (27) Nimmual, P.; Tummatorn, J.; Boekfa, B.; Thongsornkleeb, C.; Ruchirawat, S.; Piyachat, P.; Punjajom, K. Construction of 5-aminotetrazoles via in situ generation of carbodiimidium ions from ketones promoted by TMSN<sub>3</sub>/TfOH. *J. Org. Chem.* **2019**, *84*, 5603–5613.
- (28) Ma, F.; Lei, M.; Hu, L. Acetohydrazone: A Transient Directing Group for Arylation of Unactivated C (sp<sup>3</sup>)-H Bonds. *Org. Lett.* **2016**, *18*, 2708–2711.
- (29) Dewkar, G. K.; Peddi, S.; Mosier, P. D.; Roth, B. L.; Westkaemper, R. B. Methoxy-substituted 9-aminomethyl-9, 10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT<sub>2A</sub> receptor. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5268–5271.
- (30) Sarnpitak, P.; Trongchit, K.; Kostenko, Y.; Sathalalai, S.; Gleeson, M. P.; Ruchirawat, S.; Ploypradith, P. Synthesis of Substituted 2-Arylindanes from E-(2-Stilbenyl) methanols via Lewis Acid-Mediated Cyclization and Nucleophilic Transfer from Trialkylsilyl Reagents. *J. Org. Chem.* **2013**, *78*, 8281–8296.
- (31) Akkachairin, B.; Rodphon, W.; Reamtong, O.; Mungthin, M.; Tummatorn, J.; Thongsornkleeb, C.; Ruchirawat, S. Synthesis of neocryptolepines and carbocycle-fused quinolines and evaluation of their anticancer and antiplasmodial activities. *Bioorg. Chem.* **2020**, *98*, 103732.
- (32) Ghazizadeh, J.; Hamedeyazdan, S.; Torbati, M.; Farajdokht, F.; Fakhari, A.; Mahmoudi, J.; Araj-khodaei, M.; Sadigh-Eteghad, S. Melissa officinalis L. hydro-alcoholic extract inhibits anxiety and depression through prevention of central oxidative stress and apoptosis. *Exp. Physiol.* **2020**, *105*, 707–720.
- (33) Seewoo, B. J.; Hennessy, L. A.; Feindel, K. W.; Etherington, S. J.; Croarkin, P. E.; Rodger, J. Validation of chronic restraint stress model in rats for the study of depression using longitudinal multimodal MR imaging. *bioRxiv* **2020**.
- (34) O'Connor, K. A.; Feustel, P. J.; Ramirez-Zamora, A.; Molho, E.; Pilitsis, J. G.; Shin, D. S. Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats. *Behav. Brain Res.* **2016**, *301*, 226–237.
- (35) Lapmanee, S.; Charoenphandhu, J.; Teerapornpuntakit, J.; Krishnamra, N.; Charoenphandhu, N. Agomelatine, venlafaxine, and running exercise effectively prevent anxiety-and depression-like behaviors and memory impairment in restraint stressed rats. *PLoS One* **2017**, *12*, No. e0187671.